FTC OKs Bristol-Myers/Teva Deal On Paraplatin
The FTC has told Bristol-Myers that the agreement doesn't raise issues under Section 5 of the Federal Trade Commission Act, according to a Form 8K filed with the Securities and Exchange Commission. The agreement was contingent upon several conditions, including approval by the FTC.
In April, Bristol-Myers Squibb and Teva Pharmaceutic...
To view the full article, register now.